Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus

Therapeutic Drug Monitoring

Volumn 28, Issue 2, 2006, Pages 269-273

  Borrows, Richard ^a   Chusney, Gary ^a   Loucaidou, Marina ^a   James, Anthony ^a   Stichbury, Jose ^a   Tromp, Jen Van ^a   Cairns, Tom ^a   Griffith, Megan ^a   Hakim, Nadey ^a   McLean, Adam ^a   Palmer, Andrew ^a   Papalois, Vassilios ^a   Taube, David ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Immunoassay; Monitoring; Tacrolimus; Tandem mass spectrometry

Indexed keywords

ANTIDIABETIC AGENT; BASILIXIMAB; CREATININE; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECIPIENT; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; TREMOR;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MASS SPECTROMETRY; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 33748187631     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000177662.11974.f3     Document Type: Article

References (17)

1. Bottiger Y, Brattstrom C, Tyden G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol. 1999;48:445-448.
2. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996;62:920-926.
3. Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996;62:900-905.
4. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001;16:1905-1909.
5. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004;75:434-447.
6. Mourad M, Malaise J, Chaib Eddour D, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47:1241-1248.
7. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31:296-298.
8. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17:606-614.
9. Staatz CE, Taylor PJ, Tett SE. Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. Ther Drug Monit. 2002;24:607-615.
10. Keevil BG, McCann SJ, Cooper DP, et al. Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2002;39:487-492.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
12. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55:713-723.
13. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349:2326-2333.
14. Murthy JN, Davis DL, Yatscoff RW, et al. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin Biochem. 1998; 31:613-617.
15. Homma M, Tomita T, Yuzawa K, et al. False positive blood tacrolimus concentration in microparticle enzyme immunoassay. Biol Pharm Bull. 2002;25:1119-1120.
16. Kinter M. Toward broader inclusion of liquid chromatography-mass spectrometry in the clinical laboratory. Clin Chem. 2004; 50:1500-1502.
17. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem. 2002;48:955-958.